A Post Marketing Safety Study of Sitagliptin Phosphate/Metformin Hydrochloride (JANUMET®) (MK-0431A-235)

Merck Sharp & Dohme (MSD)

Status: Terminated

Conditions: Diabetes Mellitus, Type 2

Treatments: Drug: Sitagliptin Phosphate/Metformin HCl (JANUMET®)

Study type: Observational

Funder types: Industry

Identifiers

NCT01357148

0431A-235

Details and patient eligibility

About

The primary objective of this study is to obtain safety information on the use of sitagliptin phosphate/metformin hydrochloride (HCl) (JANUMET®) from endocrinologists, diabetologists, internists, and general practitioners.

Enrollment: 143 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Must be taking sitagliptin phosphate/metformin HCl (JANUMET®) for the treatment of type 2 diabetes mellitus
• Treating physician must agree to provide information regarding the participant's treatment

Trial design

143 participants in 1 patient group

Participants treated with sitagliptin phosphate/metformin HCl

Treatment:

Drug: Sitagliptin Phosphate/Metformin HCl (JANUMET®)